[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-361070-105":59,"doc-detail-361070-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","assessing-tumor-heterogeneity-and-flot-folfox-induced-alterations-in-cancer-stem-cells-and-cancer-immune-checkpoint-molecules-using-patient-derived-tumor-organoids-original-research-article","Assessing tumor heterogeneity and FLOT/ FOLFOX-induced alterations in cancer stem cells and cancer immune checkpoint molecules using patient-derived tumor organoids - Original research article","","Gastric cancer remains highly lethal, with treatment failure linked to tumor heterogeneity that is hard to measure as tumors evolve and therapies reshape cellular diversity and gene/protein profiles. Patient-derived gastric tumor organoids were used to track how chemotherapy regimens (FLOT and FOLFOX) alter cancer stem cells (LGR5, CD133) and immune checkpoint molecules (MHC-I, PD-L1). Six organoids from different patients and/or tumor regions were analyzed after treatment using viability assays, organoid sizing, and flow cytometry.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/assessing-tumor-heterogeneity-and-flot-folfox-induced-alterations-in-cancer-stem-cells-and-cancer-immune-checkpoint-molecules-using-patient-derived-tumor-organoids-original-research-article/361070/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/assessing-tumor-heterogeneity-and-flot-folfox-induced-alterations-in-cancer-stem-cells-and-cancer-immune-checkpoint-molecules-using-patient-derived-tumor-organoids-original-research-article/361070.png","ImageObject",300,407,{"name":92,"@type":93},"awa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was tumor heterogeneity assessed in this study?","Question",{"text":112,"@type":113},"Tumor heterogeneity was monitored using patient-derived gastric cancer tumor organoids, enabling measurement of marker expression changes over time after chemotherapy treatment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which biomarkers were evaluated after FLOT/FOLFOX chemotherapy?",{"text":117,"@type":113},"Cancer stem cell markers (LGR5, CD133) and immune checkpoint molecules (MHC-I, PD-L1) were profiled using flow cytometry.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find about differences between patients and tumor regions?",{"text":121,"@type":113},"Organoids from different patients showed distinct expression profiles after the same chemotherapeutic regimen, and similar differences were observed across multiple regions from the same patient.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},361070,1790317402,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Precision Medicine in Immunopathology and Pharmacology-Original research article  \n| Assessing tumor heterogeneity and FLOT/ FOLFOX-induced alterations in cancer stem cells and cancer immune checkpoint molecules using patient-derived tumor organoids | International Journal of\u003Cbr>Immunopathology and Pharmacology Volume 40: 1–12 © The Author(s) 2026 Article reuse guidelines:\u003Cbr>[sagepub.com/journals-permissions](sagepub.com/journals-permissions)\u003Cbr>[DOI: 10.1177/03946320261474427](DOI: 10.1177/03946320261474427)\u003Cbr>[journals.sagepub.com/home/iji](journals.sagepub.com/home/iji)\u003Cbr>\u003Cbr>|\n| --- | --- |\n| Chih-Cheng Cheng1,*, Bor-Chyuan Su2,* , Wei-Yu Chen3,4, and Hsin-Hsien Yu1,5\u003Cbr>Abstract\u003Cbr>Background: Gastric cancer is a deadly disease with poor prognosis and unfavorable therapeutic outcomes. It is known that a major cause of treatment failure for gastric cancer is related to tumor heterogeneity. However, it is difficult to assess heterogeneity, as the composition of tumors is dynamic and cancer treatments reshape cell diversity and gene/protein expression profiles. Objective: We utilized gastric cancer patient-derived tumor organoids to monitor tumor heterogeneity and the impacts of chemotherapy (FLOTand FOLFOX)on cancer stem cells (LGR5 and CD133) and cancer immune checkpoint molecules (MHC-I and PD-L1). Methods: Six tumor organoids were established from different patients or different regions of the same tumor. The tumor organoids were used to investigate the real-time profiles of cancer stem cell marker expression and cancer immune checkpoint molecule expression after chemotherapy treatment. Tumor suppression was monitored by the propidium iodide assay and measurements of tumor organoid diameter. Expression levels of cancer stem cell markers and immune checkpoint molecules were analyzed by flow cytometry. Results: Growth of all tumor organoids could be suppressed by chemotherapy. However, diverse impacts of FLOT and FOLFOX were observed in terms of the expression profiles of cancer stem cell markers and cancer immune checkpoint molecules. In particular, tumor organoids from different patients exhibited distinct expression profiles for cancer stem cell markers and immune checkpoint molecules after treatment with the same chemotherapeutic regimen. Similar observations were made with tumor organoids derived the same patient but different tumor regions. Conclusion: Our findings demonstrated that spatial and temporal tumoral heterogeneity can be observed after treatment with chemotherapy, suggesting that repeated monitoring of tumor characteristics may be essential for clinical decision making. In addition, sampling of multiple sites at multiple time-points might be important when evaluating the impacts of chemotherapy on cancer stem cells markers and immune checkpoint molecules. |  |\n| 1Division of General Surgery, Department of Surgery, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan 2Department of Anatomy and Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan 3Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan 4Department of Pathology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan\u003Cbr>5Division of General Surgery, Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan\u003Cbr>*Equal contribution\u003Cbr>Corresponding author:\u003Cbr>Hsin-Hsien Yu, Division of General Surgery, Department of Surgery, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan; Division of General Surgery, Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, 250 Wu-Hsing Street, Taipei City 110, Taiwan. Email: [yuhsinhsien@tmu.edu.tw](yuhsinhsien@tmu.edu.tw) |  |\n\nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  \nAttribution-NonCommercial 4.0 License ([https://creativecommons.org/li","cbCaiv5VXq0zAKEI","https://ap.wps.com/l/cbCaiv5VXq0zAKEI","pdf",2974382,12,"English","# Abstract\n## Background\n## Objective\n## Methods\n## Results\n## Conclusion\n# Keywords\n# Introduction","[{\"question\":\"How was tumor heterogeneity assessed in this study?\",\"answer\":\"Tumor heterogeneity was monitored using patient-derived gastric cancer tumor organoids, enabling measurement of marker expression changes over time after chemotherapy treatment.\"},{\"question\":\"Which biomarkers were evaluated after FLOT/FOLFOX chemotherapy?\",\"answer\":\"Cancer stem cell markers (LGR5, CD133) and immune checkpoint molecules (MHC-I, PD-L1) were profiled using flow cytometry.\"},{\"question\":\"What did the study find about differences between patients and tumor regions?\",\"answer\":\"Organoids from different patients showed distinct expression profiles after the same chemotherapeutic regimen, and similar differences were observed across multiple regions from the same patient.\"}]","Assessing tumor heterogeneity and FLOT/ FOLFOX-induced alterations in cancer stem cells and cancer immune checkpoint molecules using patient-derived tumor organoids - Original research article | PDF",1790143019,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3aa1febe6083b843211efb4f8d8f05eb.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b73f056d0f4f80c243f5a32700aee68.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b396cb353449e8272246ff970641814.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f16730a6d186e58b58f08b5ca847e801.webp",980,1306]